3 Houston innovators to know this week

WHO'S WHO

This week's roundup of Houston innovators includes Sarah "Sassie" Duggleby of Venus Aerospace, Youngro Lee of Brassica, and Le Dam of myAvos. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from rocket science to fintech — recently making headlines in Houston innovation.

Sarah "Sassie" Duggleby, CEO and co-founder of Venus Aerospace

Sarah "Sassie" Duggleby of Venus Aerospace joins the Houston Innovators Podcast this week. Photo courtesy of Venus

Sarah "Sassie" Duggleby and her husband were living in Japan and considering a trip back to Texas and wishing there was a faster option than a full day of international travel — with their kids, no less. That's when Andrew Duggleby told Sassie that there actually might be an engine that could do that.

Flash forward a few years, and the husband-wife team has built a company around that idea. Venus Aerospace, originally founded in California, relocated to Houston in 2021 to establish their company in an ecosystem with the tools to advance their tech — and give their employees a good work-life balance, Sassie Duggleby explains on the Houston Innovators Podcast.

"We knew we had to find a location where we could test our engine and still be home for dinner," she says on the show. "Our company vision is 'home for dinner.' We want to fly you across the globe and have you home for dinner. And, if you work for us, we want you home for dinner." Read more.

Youngro Lee has announced funding for his latest fintech endeavor. Photo courtesy

Youngro Lee is no stranger to shaking up the finance world with a new tech-based way of doing business. One of the founders of NextSeed, Lee's newest mission is providing "investment infrastructure as a service" with his company, Brassica, which just raised $8 million in seed funding.

“The future of finance will depend on the ability of trustworthy institutions to provide secure and seamless transitions between traditional financial services and web3 innovations while complying with strict regulations and still providing great customer experience,” says Lee in the news release.

Houston-based Mercury Fund led the round with several other investors participating. Read more.

Le Dam, CEO and founder of OptiChroniX

Le Dam moved from California to Houston to build her company. Photo via LinkedIn

After years on the West Coast, Le Dam has returned to her adopted hometown of Houston — just in time to launch a new app dedicated to providing health resources and information to its users.

“I always knew that I wanted to build my business in Houston,” Dam says, mentioning the assets of the world’s largest medical center, a thriving startup community, and diverse population for whom she wants to build her technology.

The myAvos app has been designed by behavioral health scientists to set users up for long, healthy lives. Photo via Canva

Houston innovator launches holistic health and cognitive care app

download now

Meet Laura. She’s not human, but she could be the key to your aging healthfully. She’s the digital wellness coach on myAvos, a groundbreaking app that launched this week from OptiChroniX.

Now meet Le Dam, the woman behind the app. Dam is a medical doctor, as well as CEO and co-founder of OptiChroniX. While practicing medicine in her birthplace of Australia, Dam realized that her life of prescribing medications to patients who were already sick was not how she had envisioned helping people. She knew that prevention, using the five pillars of healthy aging — nutrition, activity, sleep, health, and stress — was the way to keep patients fit and happy into their golden years.

She returned to California, where she lived after leaving Houston as a youth, to work at a startup with the goal of one day heading a company of her own. She met Swiss-based COO and co-founder, Rene Gilvert, on LinkedIn.

“He was looking for a medical doctor to join his startup,” Dam recalls. “We were so well aligned that we decided to join forces.” Now, the team works remotely in locations ranging from Dam’s home in Houston to Portugal.

When the pandemic happened, Dam took the opportunity to leave the Silicon Valley and work remotely from Houston, a return that she says was always her end goal.

myAvos pairs with a user’s smart watch and harnesses their health information such as physical activity and hours slept. The user can also input additional information such as blood test results and meals eaten. The app analyzes the information provided and assesses the user’s risk for chronic illness later in life. From there, Laura coaches them on what changes they can make to live healthier lifestyles. The app even reminds users when to take their medications and shares information with designated caregivers.

The myAvos app has a comprehensive approach to health. Screenshots via avos.health

The app has been designed by behavioral health scientists to understand why you’re not exercising enough or eating right and can offer personalized motivations to get users off the couch.

Right now, the focus is on potential dementia and cognitive impairment, says Dam, but in the future, myAvos will more holistically target all preventable chronic illnesses. But dementia is one of the major causes of disability among older people around the world and people living with it is expected to triple by 2050.

“If we can empower people with health literacy, we really believe we can prevent chronic disease,” says Dam. “Forty percent of dementia is preventable. A lot of these chronic diseases are preventable. Even diabetes can be reversible.”

And she points out that the changes that can be made to help cognitive health can affect other systems as well.

“We really want to empower the individuals,” Dam says. “If we can empower people with health literacy, we really believe we can prevent chronic disease.”

And myAvos is the key. The app is based on a subscription model, allowing users full access to a risk calculator, monthly cognitive assessments, personalized lifestyle guidance, and even fun brain games to keep them sharp. It may turn out that a visit with Laura a day will keep the doctor away long into your later years.

Le Dam moved from California to Houston to build her company. Photo via LinkedIn

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME